title: Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
abstract: OBJECTIVE
  To investigate the influence of 6 months of treatment with an oral contraceptive (OC) containing 35 μ g ethinyl estradiol and 2 mg cyproterone acetate on plasma viscosity (PV) in young women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Patients with PCOS were assessed for PV before and after 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate. PV was determined by a viscometer Type 53610/I SCHOTT-Instruments, Mainz at 37°C.
  
  
  METHODS
  Subjects were recruited from the Department of Obstetrics and Gynaecology, Division of Reproductive Endocrinology at the University Hospital of Patras, Greece.
  
  
  METHODS
  The study included 66 young women with PCOS.
  
  
  METHODS
  PV.
  
  
  RESULTS
  In PCOS women as a whole, PV at baseline was 1.249 ± 0.049 mm(2)/s (n = 66). After 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate, PV was increased to 1.268 ± 0.065 mm(2)/s (p = 0.038). The difference between PV before and after 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate (Δviscosity) was 0.01864 ± 0.071452 mm(2)/s. ΔViscosity was related to ?fibrinogen (r = 0.270, p = 0.046), to Δhematocrit (r = 0.514, p = 0.09) and to Δtriglycerides (r = 0.292, p = 0.021).
  
  
  CONCLUSIONS
  Young women with PCOS presented an increased PV under OC treatment with 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
authors.affiliation: Division of Reproductive Endocrinology, University of Patras Medical School, Patras, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Markantes
authors.forename: Alexandros D
authors.initials: AD
authors.lastname: Saltamavros
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Vervita
authors.forename: Anastasia K
authors.initials: AK
authors.lastname: Armeni
authors.forename: Anastasia
authors.initials: A
authors.lastname: Karela
authors.forename: George
authors.initials: G
authors.lastname: Adonakis
authors.forename: George
authors.initials: G
authors.lastname: Decavalas
authors.forename: Neoklis A
authors.initials: NA
authors.lastname: Georgopoulos
mesh_terms: D000293:Adolescent; D000328:Adult; D001809:Blood Viscosity / Q000187:drug effects*; D015992:Body Mass Index; D002626:Chemistry, Pharmaceutical; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000494:pharmacology; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000494:pharmacology; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D014280:Triglycerides / Q000032:analysis / Q000097:blood; D055815:Young Adult
chemical_list: D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D014280:Triglycerides; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D005340:Fibrinogen